Not Signed In - AstraZeneca Submits An NDA For Sustained Release Formulation Seroquel SRTM For The Treatment Of Schizophrenia
Sat, 22 Jul 2006 01:00 PM EST
... AstraZeneca today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration for a sustained release (SR) once-daily formulation of SEROQUEL for the treatment of patients with schizophrenia. [click link for full article] ...
Related Topics
- Quetiapine
- Schizophrenia
- Clozapine
- Acetazolamide Sustained-Release
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Ziprasidone
- Phentermine Sustained Release
- Bupropion Sustained-Release (Zyban)
- Paranoid Schizophrenia
- Treatment
- Schizophrenia - disorganized type
- Bupropion SR
- Niacin Extended Release
- Lovastatin Extended Release
- Treatments
- Valproic Acid Delayed or Extended-Release or Sprinkle Capsule
- Memantine
- Bexarotene Oral
- Metformin Extended-Release
- Rosuvastatin
email this page
print this page
bookmark this page
feedback on this page
